Vanderbilt Internal Medicine Residency Podcast · Jared Freitas and Terra Swanson

S6: E4 Infectious Disease: Antifungals

February 7, 2023·21 min·1 clip

Your husband knows this about your career: mycofungin only covers Candida.

Part two opens as a focused antifungal overview with second-year ID fellow Casey Smiley. The conversation does not assume listeners caught part one. Instead, it jumps right back into the practical problem of choosing fungal therapy in real clinical life. The first stop is micafungin. The running joke about it covering only Canada works as a shorthand for how often people reach for it when they feel pressure to add something broad. The discussion then makes the limitation clear. Micafungin mostly lives in the yeast bucket. That means Candida and, in a narrower way, cryptococcus. It can inhibit Aspergillus growth, which is why it shows up in prophylaxis for patients who are neutrophilic. It is not the drug for dimorphic fungi, Aspergillus treatment, or Mucor. From there the episode shifts into azoles. Fluconazole comes up as the easy one to remember because it usually does not require level monitoring, and the azoles generally have excellent bioavailability. Some other azoles do need monitoring, and the dose may need to be adjusted to the measured level. Itraconazole is the clearest example. Its absorption depends on the route and formulation. It can come as pills, liquid, or a newer extended-release form that is easier to dose but more expensive. Because of that variability, levels matter. The episode places itraconazole in a specific clinical bucket. It is the dimorphic fungi drug of choice. That includes Histoplasma. It is not a drug for Aspergillus or Mucor. It is often tolerated well enough for long treatment courses, usually at least a year. The conversation keeps circling back to the habit of using bucketed thinking. That is the point of the teaching style here. The hosts keep translating antimicrobial names into categories, indications, and blind spots instead of letting the listener memorize a list. The pacing stays conversational, with quick corrections, practical reminders, and small jokes that keep the material grounded. Near the end, the discussion broadens from drug choice to consultation habits. The fellow stresses that when you call ID, you should already have examined the patient and talked with them. It helps to have a plan in mind before you reach out. That turns the consult into a real conversation instead of a one-way instruction. The episode closes on gratitude and the sense that good infectious disease care depends on both technical knowledge and bedside preparation.

As heard by us

A practical ID session that turns antifungal choices into a bedside framework.

This second half of the Ask an ID Fellow discussion stays grounded in antifungal treatment and keeps coming back to the practical question of what each drug class actually covers.

Read the full review in PlayNext →

Why you'd press play

You want a focused antifungal map from an ID fellow, not a lecture slide.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Vanderbilt Internal Medicine Residency Podcast